← Back to Clinical Trials
Recruiting NCT06761924

NCT06761924 Predicting Ultrasound-Guided Thoracic PVB Success in Herpetic Neuralgia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06761924
Status Recruiting
Phase
Sponsor Beni-Suef University
Condition Patient Satisfaction
Study Type INTERVENTIONAL
Enrollment 140 participants
Start Date 2025-02
Primary Completion 2025-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Ultrasound-Guided Thoracic Paravertebral nerve blockUltrasound-Guided Thoracic Paravertebral nerve block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 140 participants in total. It began in 2025-02 with a primary completion date of 2025-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to fill the knowledge gap by investigating the predictors of success for TPVB in patients with herpetic neuralgia. By identifying demographic, clinical, previous medications and procedural factors associated with positive outcomes, this research seeks to enhance the efficacy of TPVB and improve pain management strategies for patients suffering from herpetic neuralgia.

Eligibility Criteria

Inclusion Criteria: * Adults aged from18 to 70 years * Diagnosed with herpetic neuralgia. * Able and willing to provide informed consent. * ASA I - II * One dermatomal affection * Thoracic distribution Exclusion Criteria: * Contraindications to TPVB as ( Infection at site of injection, empyema , coagulopathy and neoplastic lesion occupying the paravertebral space) * Known allergies to study medications (bupivacaine, Dexamethasone). * Severe comorbidities that could interfere with study participation.

Contact & Investigator

Central Contact

Dina M Fakhry, MD

✉ drdina.mahmoud@med.bsu.edu.eg

📞 +201289998680

Principal Investigator

Dina M Fakhry, MD

PRINCIPAL INVESTIGATOR

Beni-Suef University

Frequently Asked Questions

Who can join the NCT06761924 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Patient Satisfaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06761924 currently recruiting?

Yes, NCT06761924 is actively recruiting participants. Contact the research team at drdina.mahmoud@med.bsu.edu.eg for enrollment information.

Where is the NCT06761924 trial being conducted?

This trial is being conducted at Banī Suwayf, Egypt.

Who is sponsoring the NCT06761924 clinical trial?

NCT06761924 is sponsored by Beni-Suef University. The principal investigator is Dina M Fakhry, MD at Beni-Suef University. The trial plans to enroll 140 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology